Overactive Bladder Treatment Market By Type (Anticholinergics, Mirabegron, Botox, and Others), By Application (Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Overactive bladder (OAB)is a condition which causes a sudden urge to urinate. The urge is difficult to stop, and it may lead to the involuntary loss of urine. The medication for overactive bladderrelaxes the bladder, can be helpful for relieving symptoms of overactive bladder and reducing episodes of urge incontinence. The drug includesTolterodine (Detrol, Detrol LA), Oxybutynin (Ditropan XL), Oxybutynin as a skin patch (Oxytrol), Trospium (Sanctura), Solifenacin (Vesicare), Oxybutynin gel (Gelnique, Gelnique 3%), Darifenacin (Enablex), Mirabegron (Myrbetriq), and Fesoterodine (Toviaz). OnabotulinumtoxinAalso called Botox, is a protein from the bacteria that cause botulism illness. It is used in small doses directly injected into bladder tissues, which partially paralyzes muscles.

Overactive Bladder Treatment market is estimated to reach $5.9 billion by 2030

Market Dynamics

Rising incidence of overactive bladder is boosting the global overactive bladder treatment market. For instance, Globally, around 16% of adults have symptoms of overactive bladder (urgency with frequency and/or urge incontinence), andthe prevalence increases with age. Overactive bladder affected an estimated 33 million people in the USA in 2018.Around16% of men and 17% of women over 18 years old have overactive bladder (OAB) in 2018.In 2018 women between the ages of 20 and 45, the prevalence of overactive bladder is 36.8%. 1 in 5 adults over 40 are affected by OAB or recurring symptoms of urgency and frequency. Overactive bladder (OAB) affects more than 22 million people in Europe. Around 21% of the overactive bladderpopulation presented with incontinence, giving an overall prevalence of 11.4% for urge incontinence among Asian females. Further Increasing regulatory approval for overactive bladder treatment are key driving factors of the market. However, Side effects of overactive bladder medication might hamper the market growth. For instance, theoveractive bladder medication may cause dry mouth, constipation, dry or itchy eyes, indigestion, urinary tract infection, blurred vision, urinary retention, and drowsiness. Rarely, some can experience life-threatening symptoms such as irregular heart rhythms which might hamper the market.Increasing number of clinical studies for overactive bladder would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global Overactive Bladder Treatment market is mainly classified based on Type, Distribution Channel. Type is further segmented into Anticholinergics, Mirabegron, Botox, Others. Anticholinergicis dominating the global overactive bladder treatment market by type.Anticholinergic drugsblock the muscarinic receptor and inhibit the spontaneous detrusor contractions found in overactive bladder. Anticholinergic drugs include Oxybutynin, Propantheline, Imipramine, Tolterodine, Trospium, Darifenacin, Solifenacin, and other Anticholinergic medication. Oxybutynin is the most efficient anticholinergic for overactive bladder.Oxybutynin reduces muscle spasms of the urinary tract and bladder. Oxybutynin is used to treat urgent urination, incontinence (urine leakage), and increased night-time urination.Further, the market is segmented into by Distribution Channel, the market is divided into Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity.

Regional Analysis

Based on geography, the global Overactive Bladder Treatment market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is dominating the global overactive bladder treatment market, due to the increasing regulatory approvals for overactive bladder drug. For instance, on May 21, 2019, Alembic Pharmaceuticals and Glenmark Pharmaceuticals have received FDA approval for generic solifenacin succinate tablets.Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, and urinary frequency.North America is further divided in the U.S., Canada, and Mexico. The market is further segmented into Europe, consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.
 
Competitive landscape

Key players operating in the Overactive Bladder Treatment industry include Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan, PLC, Mylan N.V, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, Johnson & Johnson

The agreement between companies to supply materials to develop Overactive Bladder drugs is boosting the market. For instance, on February 6, 2019, Codexis, Inc., have signed a supply agreement with KYORIN Pharmaceutical Co., Ltd. to supply the proprietary enzyme used in the manufacturing of vibegron, an active ingredient in Beova Tablets, for the treatment of overactive bladder. The companies are receiving regulatory approvals for the supplement used to develop Overactive Bladder drugs, which is driving the global Overactive Bladder treatment market. For instance, on May 7, 2018, Astellas Pharma Inc. has received the U.S. Food and Drug Administration approval for supplemental New Drug Application (sNDA) for the use of mirabegron in combination with muscarinic antagonist solifenacin succinate for the treatment of overactive bladder with urge urinary incontinence, urgency and urinary frequency.

Overactive Bladder Treatment Market Key Segments

By Type
• Anticholinergics
• Mirabegron
• Botox
• Others

By Distribution Channel
• Idiopathic Bladder Overactivity
• Neurogenic Bladder Overactivity

By Geography

• North America
o The U.S.
o Canada
o Mexico

• Europe
o U.K
o Germany
o France
o Italy
o Rest of Europe

• Asia Pacific
o India
o China
o Japan
o South Korea
o Rest of Asia Pacific

• South America
o Brazil
o Argentina
o Rest of South America

• Middle East & Africa
o GCC Countries
o Egypt
o South Africa
o Rest of Middle East & Africa

Key Global Overactive Bladder Treatment Industry Players

• Astellas Pharma, Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Limited
• Allergan, PLC
• Mylan N.V
• Endo International PLC
• Hisamitsu Pharmaceutical Co., Inc.
• Sanofi
• Aurobindo Pharma Limited
• Johnson & Johnson

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Overactive Bladder Treatment Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising incidence of overactive bladder
3.3.2. Increasing regulatory approval for overactive bladder treatment
3.4. Restraints
3.4.1. Side effects of overactive bladder medication
3.5. Opportunity
3.5.1. Increasing number of clinical studies for overactive bladder
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Anticholinergics
4.2.1. Market Size & Forecast
4.3. Mirabegron
4.3.1. Market Size & Forecast
4.4. Botox
4.4.1. Market Size & Forecast
4.5. Others
4.5.1. Market Size & Forecast

5. Distribution Channel Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Idiopathic Bladder Overactivity
5.2.1. Market Size & Forecast
5.3. Neurogenic Bladder Overactivity
5.3.1. Market Size & Forecast

6. Overactive Bladder Treatment Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Overactive Bladder Treatment Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Distribution Channel
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Overactive Bladder Treatment Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Distribution Channel
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Overactive Bladder Treatment Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Distribution Channel
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Overactive Bladder Treatment Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Distribution Channel
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Overactive Bladder Treatment Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Distribution Channel
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Astellas Pharma, Inc.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Astellas Pharma, Inc. Product Category, Application, and Specification
7.1.3. Astellas Pharma, Inc. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Pfizer, Inc.
7.3. Teva Pharmaceutical Industries Limited
7.4. Allergan, PLC
7.5. Mylan N.V
7.6. Endo International PLC
7.7. Hisamitsu Pharmaceutical Co., Inc.
7.8. Sanofi
7.9. Aurobindo Pharma Limited
7.10. Johnson & Johnson